Protect-1, a prospective randomized oral therapy evaluation of CCX282-B (Traficet-EN) in Crohn's disease trial

Protect-1, a prospective randomized oral therapy evaluation of CCX282-B (Traficet-EN) in Crohn's disease trial

Bibliographic Details
Main Authors:	Bekker, P, Petryka, R, Vanasek, T, Niv, Y, Marlicz, K, Haagen-Nielsen, O, Dahelrup, J, Dotan, I, Compel, V, Keshav, S, Schall, T
Format:	Conference item
Published:	2008

Similar Items

PROTECT-1: A prospective randomized trial of CCX282-B (Traficet-EN), a novel oral therapy targeting chemokine receptor 9 in Crohn's disease
by: Keshav, S, et al.
Published: (2007)

Traficet-EN (CCX282-B), an orally active inhibitor of chemokine receptor CCR9, for treatment of Crohn's disease
by: Bekker, P, et al.
Published: (2007)

PROTECT-1 Maintenance Phase Study Results demonstrate efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Crohn's Disease
by: Bekker, P, et al.
Published: (2009)

PROTECT-1 Study Demonstrated Efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Treatment of Patients with Moderate to Severe Crohn's Disease
by: Keshav, S, et al.
Published: (2009)

Ccx282-B, an orally active inhibitor of chemokine receptor Ccr9, shows anti-inflammatory and clinical activity in the treatment of Crohn's disease
by: Keshav, S, et al.
Published: (2007)

Traficet-EN, an oral CCR9-specific antagonist, induces high levels of remission in the open-label phase of PROTECT-1 in Crohn's disease
by: Bekker, P, et al.
Published: (2008)

Traficet-EN, an Oral CCR9-Specific Antagonist, induces high levels of remission in the open-label Phase of PROTECT-1 in Crohn's Disease
by: Bekker, P, et al.
Published: (2008)

MEDI 167-Discovery of the highly potent, selective and orally bioavailable CCR9 antagonist CCX282-B
by: Ungashe, S, et al.
Published: (2008)

Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease.
by: Walters, M, et al.
Published: (2010)

CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity.
by: Kathleen M C Sullivan, et al.
Published: (2023-01-01)

Therapeutic recommendations in HFE hemochromatosis for p.Cys282Tyr (C282Y/C282Y) homozygous genotype
by: Adams, P, et al.
Published: (2018)

Expression of CCR8 and CCX-CKR on Basophils in Chronic Urticaria Is Amplified by IgE-Mediated Activation
by: Ewa A. Bartko, et al.
Published: (2023-05-01)

Medical management of Crohn's disease.
by: Cummings, JR, et al.
Published: (2008)

Oral manifestations of Crohn's disease
by: Marković Ljiljana, et al.
Published: (2004-01-01)

Mat 282- Pengiraan Kejuruteraan I
by: PPSM, Pusat Pengajian Sains Matematik
Published: (2004)

Contribuíram nesta edição (28.2)
Published: (2020-06-01)

Contribuíram nesta edição (28.2)
Published: (2020-06-01)

High-Pressure Cooling in Finishing Turning of Haynes 282 Using Carbide Tools: Haynes 282 and Inconel 718 Comparison
by: Antonio Díaz-Álvarez, et al.
Published: (2021-11-01)

282 COLPOSUSPENSION, DOES SUTURE MATERIAL MATTER?
by: S Kay, et al.
Published: (2022-06-01)

Draft genome sequence of the model naphthalene-utilizing organism Pseudomonas putida OUS282
by: Tay, Martin, et al.
Published: (2019)

ZAE 282/3 - SAINS BAHAN SEPT 1997.
by: PPSF, Pusat Pengajian Sains Fizik
Published: (1997)

ZAE282-3 - MATERIAL SCIENCES - NOVEMBER 2008.
by: PPSF, Pusat Pengajian Sains Fizik
Published: (2008)

MAT 282 - Engineering Computation I November 2006
by: PPSM, Pusat Pengajian Sains Matematik
Published: (2006)

MAT 282 - Pengiraan Kejuruteraan I - Oktober 2004
by: PPSM, Pusat Pengajian Sains Matematik
Published: (2004)

Genomic characteristics of an avipoxvirus 282E4 strain
by: Lingcong Deng, et al.
Published: (2023-10-01)

Non-alcoholic fatty liver disease in hemochromatosis probands with iron overload and HFE p.C282Y/p.C282Y
by: James C. Barton, et al.
Published: (2023-04-01)

Platelet counts in HFE p.C282Y/p.C282Y and wt/wt post-screening clinical evaluation participants
by: James C. Barton, et al.
Published: (2023-12-01)

ORAL MANIFESTATIONS OF CROHN'S DISEASE: A CASE REPORT
by: Muhvić-Urek Miranda, et al.
Published: (2015-12-01)

Oral Manifestations of Crohn’s Disease: A Systematic Review
by: María Pilar Pecci-Lloret, et al.
Published: (2023-10-01)

Efficacy of Infliximab for the Treatment of Oral Manifestation of Crohn’s Disease
by: Aibar Aginbay, et al.
Published: (2022-11-01)

Paneth cells in Crohn's disease - Effect of NOD2/CARD15 variants
by: Abeya, M, et al.
Published: (2004)

ZAE 282E/3 - SAINS BAHAN SEP 03.
by: PPSF, Pusat Pengajian Sains Fizik
Published: (2003)

ZAE 282E-3 - MATERIAL SCIENCE OCT 2004
by: PPSF, Pusat Pengajian Sains Fizik
Published: (2004)

MAT 282 - Pengiraan Kejuruteraan 1 (September/Oktober 2003)
by: PPSM, Pusat Pengajian Sains Matematik
Published: (2003)

ZAE 282E/3 - MATERIAL SCIENCE OKT 04
by: PPSF, Pusat Pengajian Sains Fizik
Published: (2004)

Meta-Dynamic Recrystallization in the Ni-Based Superalloy Haynes 282
by: Emil Eriksson, et al.
Published: (2023-07-01)

Microstructural Evolution of Large Cast Haynes 282 at Elevated Temperature
by: Yujin Yang
Published: (2021-07-01)

Response of monocytes to MDP in Crohn's disease: Effect of NOD2 mutations
by: Chalmers-Watson, T, et al.
Published: (2005)

Crohn’s disease or Crohn’s diseases?
by: Arnott, I, et al.
Published: (2003)

Paneth cells in Crohn's disease - Effect of NOD2/CARD15 variants
by: Abeya, M, et al.
Published: (2004)